Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (SHA:600866)
4.090
+0.090 (2.25%)
Oct 23, 2026, 3:00 PM CST
SHA:600866 Revenue
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong had revenue of 4.45B CNY in the quarter ending June 30, 2026, with 7.98% growth. This brings the company's total for the last twelve months to 15.93B, down -6.34% year-over-year. In the year 2025, Star Lake Bioscience Co., Inc.Zhaoqing Guangdong had annual revenue of 15.90B, down -8.27%. That makes Star Lake Bioscience Co., Inc.Zhaoqing Guangdong the 4,441st largest company in the world by revenue and 564th in China.
Revenue (ttm)
15.93B
Revenue Growth
-6.34%
P/S Ratio
0.42
Revenue / Employee
1.51M
Employees
10,528
Market Cap
6.80B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHA:600866 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.90B | -1.43B | -8.27% |
| Dec 31, 2024 | 17.33B | -39.32M | -0.23% |
| Dec 31, 2023 | 17.37B | -112.59M | -0.64% |
| Dec 31, 2022 | 17.49B | 13.42B | 329.51% |
| Dec 31, 2021 | 4.07B | 2.95B | 264.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurisco Pharmaceutical | 1.70B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.69B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Chengdu Kanghua Biological Products | 1.21B |
| Bio-Thera Solutions | 1.01B |
| Zhejiang Ausun Pharmaceutical | 778.50M |
| Daan Gene | 746.91M |
| Jiangsu Aidea Pharmaceutical Group | 722.54M |